Case Report: The Effect of Pentazocine Abuse in a Female Sickle Cell Disease Patient in Calabar, South-south, Nigeria

Main Article Content

Akaba Kingsley
Essien Ofonime
Bassey O. Bassey
Onyeulor Eberechi
Edidiong Ekang
Edakabasi Akaba
Dike Adaobi
Omini Godwin


Background: Pentazocine is a synthetic opioid analgesic with mixed receptor activities. It acts as a partial agonist at the µ-receptor as well as being a kappa agonist. Its analgesic effect is estimated to be about 25-50% greater than that of morphine. Pentazocine acts has a short onset of action which occur about 10-20 minutes after administration and could last 2-4hours.

Aim: The study was aimed at further awakening the consciousness of this growing menace among people living with sickle cell disease as well as proffering solutions to curtail this increasing peril.  

Presentation of Case: A 36 years old Nigerian female with three years history of excessive use of parenteral pentazocine on account of sickle cell bone pain crisis. She commenced self-administration after exposure by a private hospital on account of bone pain crisis where other analgesic fails to give her the necessary relieve. Hence, the beginning of her dependency.  She started with two ampules daily and later increased to 20 ampules on the account of this, patient was said to have developed cutaneous and musculoskeletal complication. A diagnosis of pentazocine addiction in a SCD patient was made, she was admitted and jointly managed by a Psychiatrist, Phychologist, Haematologist and Plastic Surgeon. We hereby advocate for effective legislation, orientation and reorientation of health workers and the society at large about the risks and complication of parenteral pentazocine abuse. This menace can possibly be curtailed if oral formulation is made available and less addictive medications are used.  

Conclusion: Analgesics that are less addictive should be administered after examining the nature of pain before furtherance to stronger analgesic which could predispose to addiction.

Pentazocine abuse, sickle cell disease, opioid, bone pain crisis.

Article Details

How to Cite
Kingsley, A., Ofonime, E., Bassey, B., Eberechi, O., Ekang, E., Akaba, E., Adaobi, D., & Godwin, O. (2019). Case Report: The Effect of Pentazocine Abuse in a Female Sickle Cell Disease Patient in Calabar, South-south, Nigeria. Journal of Pharmaceutical Research International, 29(5), 1-7.
Case Study


Akaba K, Ibanga I, Oshatuyi O, Essien O, Onyeulor E, Ntomchukwu C, Ekpenyong U. Case report: Successful management of opioid and addiction in a known SCD patient at the University of Calabar Teaching Hospital, Calabar Nigeria. International Journal of Research and Reports in Hematology. 2018;1(1):1-5.

Akaba K, Ofem E, Bassey OB, Babatope O, Riman O. Biochemical assessement of the liver in SCD in a tertiary hospital in South-South, Nigeria. Journal of Advances in Medicine and Medical Research. 2019;29(7):1-6.

Nwogoh B, Adewoyin AS, Iheanacho OE, Bazuaye GN. Psrevalence of haemoglobin variant in Benin City, Nigeria. Annals of Biomedical Science. 2012;11(2):60-64.

Inyama M, et al. Stroke prevalence among sickle cell patients in Nigeria a multi-centre study. Africa Health. 2014;14(2):446-452.

Elander J, Lusher J, Bevan D, Telfer P. Pain management and symptoms of substance dependence among patients with sickle cell disease. Soc Sci Med. 2003;57(9):1683-1696.

Winifield J, Greek K, Cutaneous complications of parenterally administered pentazocine injection. JAMA. 1973;226: 189-190

Silva M, Sing P, Murthy P. Fibromyositis after intramuscular pentazocine abuse. J. Postgrad. Med. 2002;48:239.

Steiner J, Winkleman A, De Jesus P. Pentazocine-induced myopathy. Arch Neurol. 1973;28:408-409.

Reid MC, Henerson CR, Amanfo L. Characteristics of older adults receiving opioids in primary care; treatment duration and outcomes. Pain Med. 2010;11:1063-1071.

Trescot AM, Helm S, Hansen H, Benjamin R, Glaser SE. Opioids in the management of chronic non-cancer pain: an update of American society of the interventional pain physicians’ (ASIPP) Guidelines. Pain Physicians. 2008;11:5-62.

Kotila TR, Busari OE, Makanjuola V, Eyelade OR. Addiction or pseudoaddiction in sickle cell disease patients. Time to decide- a case series. Ann Ib Post grad Med. 2015;13:44-47.

Okpala I, Tawil A. Management of pain in sickle cell disease. JR Soc Med. 2002;95: 456-458.

Kotila T. Management of acute painful crisis in sickle cell disease clinical and laboratory haematology. 2005;27(4):221-223.

Mabayoje VO, Adeyemo MA, Akinola NO. Case review: Drug addiction in sickle cell disease, a possible ongoing challenge in management of pain? Journal of Global Bioscience. 2015;4(4):2021-2025.

Ahmed SG, Ibrahim UA. The prevalence of therapeutic opiate dependence among patient with sickle cell disease in Maiduguri, North-East Nigeria. Nigerian Journal of Pharmacy. 2001;32:56-59.

Iheanacho OE, Ezenwenyi IP, Enosolease MG. Pentazocine abuse in sickle cell disease patient seen at a tertiary hospital in Nigeria: A chronic menace. International Journal of Tropical Disease & Health. 2015; 9(1):1-8.

Akaba K, Inyama M, Ekwere T, Iheanacho O, Bassey E, Ushie G, Archibong H and Efiok E. Haemostatic disorders in sickle cell disease subjects in Nigeria: A review of literature. IBRR. 2018;8(4):1-7.